Calando plans to start clinical trials of RNAi therapeutic by end of 2007

By Lisa Kerner

Charlotte, N.C., Sept. 6 - Calando Pharmaceuticals Inc. said it plans to advance its first experimental RNAi therapeutic toward phase 1 trials in solid tumors before the end of 2007.

"Calando's therapeutic is a targeted RNAi therapeutic designed de novo," founder Mark Davis said in a company news release.

"It combines synthetic delivery components with targeting agents and siRNAs that do not require chemical modification to create the first of its kind nanoparticulate therapeutic for cancer."

The company filed for patent protection of its siRNA sequences for the gene target, licensed key siRNA patents from Alnylam Pharmaceuticals Inc. and plans to file an Investigational New Drug application with the Food and Drug Administration.

Pasadena, Calif.-based Calando uses proprietary polymeric delivery systems technologies and siRNA design to create targeted siRNA therapeutics. It is a majority owned subsidiary of Arrowhead Research Corp.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.